WO2008019303A3 - Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors - Google Patents
Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors Download PDFInfo
- Publication number
- WO2008019303A3 WO2008019303A3 PCT/US2007/075146 US2007075146W WO2008019303A3 WO 2008019303 A3 WO2008019303 A3 WO 2008019303A3 US 2007075146 W US2007075146 W US 2007075146W WO 2008019303 A3 WO2008019303 A3 WO 2008019303A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- present
- serine protease
- hepatitis
- pyridazinonyl
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof, which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49984406A | 2006-08-04 | 2006-08-04 | |
US11/499,844 | 2006-08-04 | ||
US11/832,893 US7718612B2 (en) | 2007-08-02 | 2007-08-02 | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors |
US11/832,893 | 2007-08-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008019303A2 WO2008019303A2 (en) | 2008-02-14 |
WO2008019303A3 true WO2008019303A3 (en) | 2008-10-30 |
Family
ID=39033583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/075146 WO2008019303A2 (en) | 2006-08-04 | 2007-08-03 | Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors |
Country Status (4)
Country | Link |
---|---|
CO (1) | CO6020004A1 (en) |
EC (1) | ECSP077649A (en) |
PE (1) | PE20080539A1 (en) |
WO (1) | WO2008019303A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9227940B2 (en) | 2002-05-20 | 2016-01-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI387603B (en) | 2005-07-20 | 2013-03-01 | Merck Sharp & Dohme | Hcv ns3 protease inhibitors |
DE602006019323D1 (en) | 2005-10-11 | 2011-02-10 | Intermune Inc | COMPOUNDS AND METHOD FOR INHIBITING THE REPLICATION OF THE HEPATITIS C VIRUS |
KR20090024834A (en) | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | Novel inhibitors of hepatitis c virus replication |
US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
UY32099A (en) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | HEPATITIS C SERINA PROTEASAS MACROCYCLIC INHIBITORS |
US8377962B2 (en) | 2009-04-08 | 2013-02-19 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
US8703700B2 (en) * | 2009-05-22 | 2014-04-22 | Sequoia Pharmaceuticals, Inc. | Bimacrocylic HCV NS3 protease inhibitors |
US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
AR077712A1 (en) | 2009-08-05 | 2011-09-14 | Idenix Pharmaceuticals Inc | SERINA PROTEASA MACROCICLICA INHIBITORS |
EA201201031A1 (en) | 2010-01-25 | 2013-02-28 | Энанта Фармасьютиклз, Инк. | HEPATITIS C VIRUS INHIBITORS |
US8933110B2 (en) | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
AU2011352145A1 (en) | 2010-12-30 | 2013-07-18 | Abbvie Inc. | Phenanthridine macrocyclic hepatitis C serine protease inhibitors |
MX2013007677A (en) | 2010-12-30 | 2013-07-30 | Abbvie Inc | Macrocyclic hepatitis c serine protease inhibitors. |
WO2012109398A1 (en) | 2011-02-10 | 2012-08-16 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
MX360452B (en) | 2012-10-19 | 2018-11-01 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors. |
US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
WO2014070974A1 (en) | 2012-11-05 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US9310374B2 (en) | 2012-11-16 | 2016-04-12 | Redwood Bioscience, Inc. | Hydrazinyl-indole compounds and methods for producing a conjugate |
WO2014137869A1 (en) | 2013-03-07 | 2014-09-12 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004072243A2 (en) * | 2003-02-07 | 2004-08-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis c serine protease inhibitors |
US20040180815A1 (en) * | 2003-03-07 | 2004-09-16 | Suanne Nakajima | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors |
US20050153877A1 (en) * | 2003-02-07 | 2005-07-14 | Zhenwei Miao | Macrocyclic hepatitis C serine protease inhibitors |
-
2007
- 2007-08-03 WO PCT/US2007/075146 patent/WO2008019303A2/en active Application Filing
- 2007-08-06 EC EC2007007649A patent/ECSP077649A/en unknown
- 2007-08-06 CO CO07080060A patent/CO6020004A1/en not_active Application Discontinuation
- 2007-08-06 PE PE2007001036A patent/PE20080539A1/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004072243A2 (en) * | 2003-02-07 | 2004-08-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis c serine protease inhibitors |
US20050153877A1 (en) * | 2003-02-07 | 2005-07-14 | Zhenwei Miao | Macrocyclic hepatitis C serine protease inhibitors |
US20040180815A1 (en) * | 2003-03-07 | 2004-09-16 | Suanne Nakajima | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9227940B2 (en) | 2002-05-20 | 2016-01-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
Also Published As
Publication number | Publication date |
---|---|
PE20080539A1 (en) | 2008-05-16 |
CO6020004A1 (en) | 2009-03-31 |
ECSP077649A (en) | 2008-03-26 |
WO2008019303A2 (en) | 2008-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008019303A3 (en) | Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors | |
WO2007143694A3 (en) | Macrocyclic oximyl hepatitis c protease inhibitors | |
WO2008021960A3 (en) | Triazolyl macrocyclic hepatitis c serine protease inhibitors | |
WO2008022006A3 (en) | Arylalkoxyl hepatitis c virus protease inhibitors | |
WO2008019289A3 (en) | Tetrazolyl macrocyclic hepatitis c serine protease inhibitors | |
WO2008021956A3 (en) | Acylaminoheteroaryl hepatitis c virus protease inhibitors | |
WO2008019266A3 (en) | Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors | |
WO2008021871A3 (en) | Triazolyl acyclic hepatitis c serine protease inhibitors | |
WO2008002924A3 (en) | Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors | |
WO2009076166A3 (en) | Oximyl hcv serine protease inhibitors | |
WO2008021733A3 (en) | Tetrazolyl acyclic hepatitis c serine protease inhibitors | |
MX2010005261A (en) | Macrocyclic tetrazolyl hepatitis c serine protease inhibitors. | |
WO2009053828A3 (en) | P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors | |
MX2010006518A (en) | Macrocyclic oximyl hepatitis c serine protease inhibitors. | |
MX2010006209A (en) | Quinoxalinyl derivatives. | |
MX2010005262A (en) | Quinoxaline-containing compounds as hepatitis c virus inhibitors. | |
MX2010010276A (en) | Fluorinated macrocyclic compounds as hepatitis c virus inhibitors. | |
WO2009076173A3 (en) | Fluorinated tripeptide hcv serine protease inhibitors | |
WO2004093798A3 (en) | Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors | |
WO2004113365A3 (en) | Hepatitis c serine protease tri-peptide inhibitors | |
MX2011012155A (en) | Macrocyclic compounds as hepatitis c virus inhibitors. | |
WO2011049908A3 (en) | Bismacrokyclic compounds as hepatitis c virus inhibitors | |
MX2019013037A (en) | Macrocyclic proline derived hcv serine protease inhibitors. | |
WO2009085978A8 (en) | Bridged carbocyclic oxime hepatitis c virus serine protease inhibitors | |
MX2010008109A (en) | Difluorinated tripeptides as hcv serine protease inhibitors. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07799997 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07799997 Country of ref document: EP Kind code of ref document: A2 |